TYRA
Tyra Biosciences, Inc.
Healthcare · Biotechnology · NMS
$33.17
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$2.0B
Trailing P/E
Forward P/E
-11.69
Rev Growth
Profit Margin
0.0%
ROE
-36.9%
Analyst Target
$53.00
Recommendation
STRONG BUY
About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow0.0
Moat40.0
Balance Sheet44.8
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: WATCH · Score: 36.5 · Rank: #4660
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$1.6B
Price/Book
6.77
Beta
0.789
Analysts
11
Total Debt
$5.7M
Rec. Mean
1.29
Short Ratio
8.82
Short % Float
0.3%
Employees
87

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 11 analysts at Strong Buy.
Price: $33.17 | Target: $51.15 (+54%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+54%
The Fundamentals
Profit Margin0.0%
ROE-36.9%
Forward P/E-11.7
Market Cap$2.0B
Position Sizing Scenarios
Stop: $28.19 (-15%) | Entry: $33.17
SharesCostProfit to TargetR:R
To Consensus ($51.15, 11 analysts)
10$331.70+$179.80 (54%)3.6R
50$1,658.50+$899.00 (54%)3.6R
100$3,317.00+$1,798.00 (54%)3.6R
Risk Factors
  • Elevated short interest (8.82 days to cover)
The Verdict
Tyra Biosciences, Inc. holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
54.0
Risk Grade
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-5.4%
worst expected daily loss, 19 in 20 days
CVaR 95%
-8.0%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
0.87
above 1.0 is good
Max Drawdown
-75.3%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
65
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
NEAR_LOWER
Beta
Relative Volume
0.9x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
NRIX0.412
KYMR0.402
RCUS0.390
ARKG0.389
AURA0.376
Inverse Correlated
TickerCorrelation
PSO.KA-0.137
SMWH.L-0.135
ULVR.L-0.135
ZAIN.KW-0.134
SENERGY.KW-0.127
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Thursday
Worst Day
Friday
Best Month
Jul
Worst Month
Oct
Fri-Mon Effect
-0.08206133051919445
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-6.8%
3M Return
-1.5%
6M Return
+46.8%
12M Return
+270.5%
Momentum Rank
#484
Momentum Signal
STRONG_UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access